Sionna Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Sionna Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $75.3 million for 2025 while advancing its lead cystic fibrosis product candidates, SION-719 and SION-451, into later-stage clinical trials.
NASDAQ
Sionna Therapeutics' 10-K filing details its ongoing clinical trials and development of novel medicines for cystic fibrosis (CF), focusing on NBD1 stabilizers and complementary modulators.